Alere International has announced the launch of its new Triage NT-proBNP test. Used in conjunction with clinical assessment, the NT-proBNP (N-terminal pro B-type natriuretic peptide) test is a useful biomarker in the diagnosis and management of patients with heart failure. The new test expands Alere’s point-of-care Triage cardiovascular testing solutions.
Heart failure can often be confused with other conditions, such as lung disease, which is why an accurate diagnosis is important to ensure the most appropriate treatment and care is in place. B-type natriuretic peptide (BNP) and NT-proBNP levels can help clinicians differentiate heart failure and other problems, as the level of natriuretic peptides in the blood increases as chronic heart failure advances.
The Alere Triage NT-proBNP test is CE-marked, which expresses conformity with the requirements of the European IVD Directive and allows distribution within the European Union. The test is now available for commercial sale in Europe and will soon be available in many other countries around the world.